Associated Papers
Impact of genetic polymorphisms and drug-drug interactions mediated by carboxylesterase 1 on remimazolam deactivation.
Wang Z et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
Regulation of Human Hydrolases and Its Implications in Pharmacokinetics and Pharmacodynamics.
Jung SM et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Pharmacogenetic study of CES1 gene and enalapril efficacy.
Hussain M et al.
Journal of Applied Genetics, 2024
Discovery of a novel homocysteine thiolactone hydrolase and the catalytic activity of its natural variants.
Hou S et al.
Protein Science : a Publication of the Protein Society, 2024
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.
Fricke-Galindo I et al.
Viruses, 2021
Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.
Her L et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2020
Is genetic variability in carboxylesterase-1 and carboxylesterase-2 drug metabolism an important component of personalized medicine?
Laizure SC et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Functional Study of Carboxylesterase 1 Protein Isoforms.
Wang X et al.
Proteomics, 2019
Clinical implications of genetic variation in carboxylesterase drug metabolism.
Chen F et al.
Expert Opinion on Drug Metabolism & Toxicology, 2018
The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.
Oh J et al.
Plos One, 2017
Select a paper to view details